H.C. Wainwright initiated coverage of Sana Biotechnology with a Neutral rating and no price target. Although preclinical data and an experienced management team "add promise" to Sana’s approach, the company’s programs are still in the early innings, and its market cap of $1B is pricing in a high probability of success, the analyst tells investors in a research note. The firm believes this creates an unfavorable risk/reward going into initial clinical data in the second half of 2023.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on SANA:
- Sana Biotechnology Announces the Acceptance of Six Abstracts for Presentation at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting
- Sana Biotechnology to Host Research & Development Day
- Sana Biotechnology Highlights Preclinical Hypoimmune Data for its Allogeneic CAR T Platform and Advancements with its In Vivo Fusogen Platform with Four Presentations at the 2023 AACR Annual Meeting
- Sana Biotechnology announces preclinical data published on CAR T cells
- Sana Biotechnology Announces Preclinical Data Published in Nature Communications Demonstrating the Ability of its Hypoimmune Allogeneic CD19-directed CAR T Cells to Evade Immune Rejection and Produce Durable Anti-Tumor Responses
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue